Access cutting-edge parkinson's disease treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access parkinson's disease specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related parkinson's disease treatment provided free
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Sponsor: Cerevance
Check if you qualify for this parkinson's disease clinical trial in Palo Alto, CA
If you're searching for parkinson's disease treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced parkinson's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.